Soluble CD40 ligand in haemodialysis patients: survival impact and cardiovascular prognostic role

Context: Soluble CD40 ligand (sCD40l) can predict cardiovascular events (CVE) and mortality in haemodialysis (HD) patients (short-, medium-term follow-up studies). Objective: To evaluate the relationship between sCD40l and survival, CVE and mortality in HD patients on long-term follow-up. Methods: W...

Full description

Saved in:
Bibliographic Details
Published inBiomarkers Vol. 22; no. 3-4; pp. 232 - 238
Main Authors Rusu, Crina, Racasan, Simona, Moldovan, Diana, Kacso, Ina Maria, Potra, Alina, Bondor, Cosmina Ioana, Patiu, Ioan Mihai, Vladutiu, Dan, Caprioara, Mirela Gherman
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 19.05.2017
Subjects
C-Reactive Protein - analysis
Cardiovascular disease
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - etiology
CD40 Ligand - blood
Female
Humans
immunotoxicity
Male
Middle Aged
Prognosis
Renal Dialysis
renal disease
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - diagnosis
Renal Insufficiency, Chronic - mortality
Survival Rate
Cardiovascular disease
immunotoxicity
renal disease
Online AccessGet full text

Cover

More Information
Summary:Context: Soluble CD40 ligand (sCD40l) can predict cardiovascular events (CVE) and mortality in haemodialysis (HD) patients (short-, medium-term follow-up studies). Objective: To evaluate the relationship between sCD40l and survival, CVE and mortality in HD patients on long-term follow-up. Methods: We registered 46 HD patients' baseline characteristics, mortality and CVE for 108 months. Results: SCD40l correlated positively with C-reactive protein, was higher in survivors, but had no impact on survival and was not predictive for CVE or CV mortality. Conclusion: The levels of sCD40l have no influence on survival or CVE and mortality in HD patients in a long-term follow-up.
ISSN:1354-750X
1366-5804
DOI:10.1080/1354750X.2016.1201531